January 26th Lunch & Learn Event on Sjogren’s Syndrome PDF Print E-mail
Thursday, 07 January 2010 12:16
For those of you in the state of Texas, Northwest Rheumatology, a division of Northwest Diagnostic Clinic, will host a free Lunch & Learn event on Sjogren’s Sydrome: The Forgotten Disease on Tuesday, Jan. 26, from 11:45 a.m. – 1 p.m. at the South Montgomery County Woodlands Chamber of Commerce Board Room.

Dr. Tamar Brionez of Northwest Rheumatology will speak on the definition, symptoms and therapeutics of Sjogren’s Syndrome, a disease often undiagnosed or misdiagnosed due to symptoms that mimic other medical conditions. This Lunch & Learn is the second in a quarterly series that will address a variety of health topics.

“This is a great topic to discuss,” said Dr. Brionez. “The lunch will be very informative and I look forward to addressing the questions and concerns commonly associated with Sjogren’s Syndrome. I am excited to be the next speaker in this series.”

The event is free and open to the public. Reservations are required and must be made by Friday, Jan. 22.

With four physicians on staff, Northwest Rheumatology specializes in the treatment of Rheumatoid Arthritis, Scleroderma, Sjogren’s Syndrome, Psoriatic Arthritis, Lupus and other autoimmune diseases, as well as Osteoporosis and Osteoarthritis. With offices in The Woodlands and Houston, the clinic offers several areas of expertise including family practice, internal medicine and rheumatology, as well as on-site ancillary services such as CT, MRI, nuclear medicine, ultrasound, bone density testing, infusion and laboratory services.

For more information, do click here.
 
More articles :

» Survival in Pulmonary Hypertension Associated With the Scleroderma Spectrum of Diseases

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisObjective. Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be...

» Actelion Announces FDA Approval of Brand Name, Veletri, for Pulmonary Arterial Hypertension

US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for...

» DETECT Algorithm Increases Rate Of Diagnosis For PAH In Scleroderma Patients

The use of a two-step algorithm significantly increased the rate at which pulmonary arterial hypertension was diagnosed in patients with in a prospective, observational, cross-sectional study. The results of the , presented at the annual European...

» Musculoskeletal Rehabilitation in the Person with Scleroderma

Janet L. PoolePosted: 03/12/2010; Curr Opin Rheumatol. 2010;22(2):205 © 2010 Lippincott Williams & WilkinsAbstractPurpose of Review: The purpose of this review is to examine current evidence for the efficacy of rehabilitation techniques for...

» Unite Against Scleroderma

On May 1st 2011, the would be holding its first annual "Unite Against Scleroderma" Walk around the Queen's Park Savannah, Port Of Spain. It is our aim to help raise awareness of this rare autoimmune disease and the funding needed to aid those who...

» Scleroderma-Related PAH: The Need for Early Diagnosis and Treatment

Pulmonary arterial hypertension (PAH) associated with scleroderma (systemic sclerosis) is an aggressive disorder with a poor prognosis. Effective therapies are available for PAH but patients with scleroderma-associated PAH have a poorer response to...